The International Linked Clinical Trials (iLCT) program, a collaborative effort from The Cure Parkinson’s Trust (CPT), the Van Andel Institute (VAI), and now the John Black Charitable Foundation (JBCF), has pledged $6.75 million over three years to support clinical trials of potential Parkinson’s disease treatments.
The Aligning Science Across Parkinson’s initiative has awarded a $6 million grant to a research team looking to define the molecular connections between aging and Parkinson’s disease. The three-year grant, issued by the Michael J. Fox…
Scientists have developed a new system that can provide a controlled and sustained release of parkinsonian medications, thus enabling better management of Parkinson’s disease. The mechanisms behind this delivery system were described in the study, “Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson’s Disease,” published in the…
Seelos Therapeutics has signed an agreement with Duke University in North Carolina to conduct a pre-clinical study of SLS-004, one of its gene therapy candidates, as a treatment for Parkinson’s disease. The proof-of-concept study will seek to determine if the investigational therapy can prevent or delay Parkinson’s disease…
Simvastatin, a widely-used cholesterol-lowering medication, failed to slow the progression of Parkinson’s disease, according to data from a Phase 2 trial. Based on these findings, it was decided that a future Phase 3 study assessing the safety and efficacy of simvastatin in these patients would not be…
The Aligning Science Across Parkinson’s (ASAP) initiative has awarded a $7.2 million grant to a research team working to unravel the structure and biology of leucine-rich repeat kinase 2 (LRRK2), a protein linked to familial Parkinson’s disease. The three-year grant, issued by the Michael J. Fox Foundation (MJFF), was…
Reduced protein synthesis could serve as a biomarker to help diagnose Parkinson’s disease, even before motor symptoms appear, a recent study suggests. The study, “Protein synthesis is suppressed in sporadic and familial Parkinson’s disease by LRRK2,” was published in The FASEB Journal. The LRRK2 protein (leucine-rich repeat…
Fatigue increases over time in people with Parkinson’s disease and is associated with several factors, including sex, age, depression symptoms, and higher cognitive function, a study has found. The results of the longitudinal study, “Progression of fatigue in Parkinson’s disease – A nine-year follow-up,” were published…
Cognitive changes in people with Parkinson’s disease pose a substantial challenge for their care partners, new research suggests. The findings were presented at the 2020 Congress of Parkinson’s Disease and Movement Disorders (held virtually due to the COVID-19 pandemic) by researchers from the Parkinson’s Foundation, in…
A new webinar titled “Is Parkinson’s Inherited?” — led by a research vice president at the Michael J. Fox Foundation (MJFF) — focused on the genetics and heritability of Parkinson’s disease and spoke to the need for greater diversity in clinical trials. The MJFF’s latest Third Thursday Webinar,…
Get regular updates to your inbox.
